Comparison of the effects of 3,5,3′-triiodothyroacetic acid and triiodothyronine on goiter prevention and involution and on hepatic and skeletal parameters in rats

Hormone and Metabolic Research

Volumn 36, Issue 5, 2004, Pages 291-297

  Alvarez, L ^a   Burgueno A ^a   Zeni, S ^b   Randi, A S ^a   Hernandez S ^a   Hockl, P ^c   Pisarev, M A ^a,d   Kleiman De Pisarev, D L ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^c INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^d DEPARTAMENTO DE FÍSICA   (Argentina)

Author keywords

Bone formation; Bone resorption; L glycerol 3 p dehydrogenase; Malic enzyme; Methimazole induced goiter; Thyroid growth

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; ISOENZYME; LIOTHYRONINE; LIVER ENZYME; MALATE DEHYDROGENASE (DECARBOXYLATING); ORNITHINE DECARBOXYLASE; THIAMAZOLE; THYROID HORMONE; TIRATRICOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GOITER; HYPOPHYSIS FUNCTION; LIVER FUNCTION; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SKELETON;

ANIMALS; BONE AND BONES; BONE DENSITY; DISEASE MODELS, ANIMAL; FEMALE; GOITER; LIVER; RATS; RATS, WISTAR; THYROTROPIN; TRIIODOTHYRONINE;

ANIMALIA;

EID: 2542639997     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814485     Document Type: Article

References (53)

1. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfman SG. Treatment guidelines for patients with thyroid nodules an well-differentiated thyroid cancer. Arch Intern Med 1996; 156: 2165-2172
2. Gharib H. Changing concepts in the diagnosis and management of thyroid nodules. Endocrinol Metab Clin North Am 1997; 26: 777-800
3. Gullu S, Gurses A, Baskal N, Uysal AR, Kamel AN, Erdogan G. Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Endocr J 1999; 46: 221-226
4. Lima N, Knobel M, Cavaliere H, Sztejnsznajd C, Tominmori E, Medeiros-Neto G. Levothyroxine suppressive therapy is partially effective in treating patients with benign solid thyroid nodules and multinodular goiters. Thyroid 1997; 7: 691-697
5. Paggi A, Persegani-Trimarchi C, Russo P, Mastropasqua M, Mosetti MA, Losi T, Leri O. Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy. Endocrinol Res 1999; 25: 229-238
6. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular disease. Ann Intern Med 1998; 18: 386-394
7. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1998; 130: 350-356
8. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19: 35-62
9. Baran DT, Braverman LE. Thyroid hormones and bone mass. J Clin Endocrinol Metab 1991; 72: 1182-1183
10. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81: 4278-4289
11. Stall GM, Harris S, Skoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients over-treated with L-thyroxine. Ann Int Med 1990; 113: 265-269
12. Hadji P, Hars O, Sturm G, Bauer T, Emons G, Schulz K. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. Eur J Endocrinol 2000; 142: 445-450
13. Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M, Sacca L. Impaired cardiac reserve and exercise capacity in patients receiving lon-term thyrotropin suppressive therapy with levotyroxine. J Clin Endocrinol Metab 1996; 81: 4224-4228
14. Muller CG, Bayley TA, Harrison JE, Tsang R. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 1995; 5: 81-87
15. Hawkins F, Rigopoulou D, Papapietro K, Lopez MB. Spinal bone mass after long term treatment with L-thyroxin in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcif Tissue Int 1994; 54: 16-19
16. 3. Mol Endocrinol 1990; 4: 227-234
17. Takeda T, Suzuki S, Liu R-T, DeGroot LJ. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab 1995; 80: 2033-2040
18. Oppenheimer JH, Schwartz HL, Surks MI. Determination of common parameters of iodothyronine metabolism and distribution in man by non compartmental analysis. J Clin Endocrinol Metab 1975 (a); 41: 319-324
19. Oppenheimer JH, Schwartz HL, Surks MI. Erratum: revised calculations of common parameters iodo-thyronine metabolism and distribution by noncompartmental analysis. J Clin Endocrinol Metabol 1975 (b); 41: 1172-1173
20. Goslings B, Schwartz HL, Dillmann W, Surks MI, Oppenheimer JH. Comparison of the metabolism and distribution of L-triiodothyronine and triiodothyroacetic acid in the rat: a possible explanation of differential hormonal potency. Endocrinology 1976; 98: 666-675
21. Jaffiol C, Baldet L, Papachristou C, Bringer J. Intérèt de l'acide triiodothyroacetique comme traitement freinateur de la sécrétion thyréotrope en pathologie thyroidienne. Presse Med 1988; 17: 57-60
22. Jaffiol C, Daures JP, Nsakala N, Guerenova J, Baldet L. Le controle a long terme du traitment médicale du cancer thyroidiene différencié. Ann Endocrinol (Paris) 1995; 56: 119-126
23. Beck-Peccoz P, Piscitelli G, Cattaneo MG, Faglia G. Succesful treatment of hyperthyroidism due to non-neoplastic pituitary TSH hypersecretion with 3′,5′,3 triiodothyroacetic acid (TRIAC). J Endocrinol Invest 1983; 6: 217-223
24. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993; 14: 348-399
25. Kunitake JM, Hartman N, Henson LC, Lieberman J, Williams DE, Wong M, Hershman JM. 3,5,3′-triiodothyroacetic acid therapy for thyroid hormone resistance. J Clin Endocrinol Metab 1989; 69: 461-466
26. Beck-Peccoz P, Sartorio A, De Medici C, Grugni G, Morabito F, Faglia G. Dissociated thyromimetic effects of 3,5,3′-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J Endocrinol Invest 1988; 11: 113-118
27. Medeiros-Neto G, Kallas WG, Knobel M, Cavaliere H, Mattar E. Triac (3,5,3′-triiodothyroacetic acid) partially inhibits the thyrotropin response to synthetic thyrotropin-releasing hormone in normal and thyroidectomized hypothyroid patients. J Clin Endocrinol Metab 1980; 50: 223-225
28. Bracco D, Morin O, Schutz Y, Liang H, Jequier E, Burger AG. Comparison of the metabolic and endocrine effects of 3,5,3′-triiodothyroacetic acid and thyroxin. J Clin Endocrinol Metab 1993; 77: 221-228
29. Sherman SI, Ringel MD, Smith MJ, Kopelen HA, Zoghbi WA, Ladenson PW. Augmented hepatic and skeletal thyromimetic effects of Tiratricol in comparison with Levothyroxine. J Clin Endocrinol Metabol 1997; 82: 2153-2158
30. Kawaguchi H, Pilbeam CC, Woodiel FN, Raisz LG. Comparison of the effects of 3,5,3′-triiodothyroacetic acid and triiodothyronine on bone resorption in cultured fetal rat long bones and neonatal mouse calvariae. J Bone Miner Res 1994; 9: 247-253
31. Liang H, Juge-Aubry CE, O'Connell M, Burger AG. Organ-specific effects of 3,5,3′-triiodothyroacetic acid in rats. Eur J Endocrinol 1997; 137: 537-544
32. Ma HT, Reuse S, Koibuchi N, Matsuzaki S. Acute inhibitory effect of excess iodide on ornithine decarboxylase in the thyroid of propylthiouracil- treated rats. J Endocrinol 1996; 150: 369-376
33. Matsuzaki S, Kakegawa T, Suzuki M, Hamana K. Thyroid function and Polyamines III. Changes in Ornithine Decarboxylase Activity and Polyamine contents in the rat Thyroid during hyperplasia and involution. Endocrinol Japon 1978; 25: 129-139
34. Hsu RY, Lardy HA. Pigeon liver malic enzyme. J Biol Chem 1967; 242: 520-526
35. Lee YP, Lardy HA. Influence of thyroid hormones on L-glycerolphosphate dehydrogenases and other dehydrogenases in various organs of the rat. J Biol Chem 1965; 240: 1427-1436
36. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
37. Farley JR, Hall SL, Llacas D. Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. Clin Chem 1994; 40: 1749-1756
38. Zeni SN, Gomez Acotto C, Mautalen C. Olpadronate prevents thyroxin-induced osteopenia in OVX rats. Bone 1997; 21: 329-333
39. Derwahl M, Broecker M, Kraiem Z. Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clinical Endocrinol Metabol 1999; 84: 829-839
40. Mirell CJ, Yanagisawa M, Hershman JM. Triac reduces serum TSH without decreasing alpha and beta TSH messenger RNAs. Horm Metab Res 1989; 21: 123-126
41. Brenta G, Schnitman M, Fretes O, Facco E, Gurfinkel M, Damilano S, Pacenza N, Blanco A, Gonzalez E, Pisarev MA. Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid. J Clin Endocrinol Metab. 2003; 88: 5287-5292
42. Richman R, Park S, Akbar M, Yu S, Burke G. Regulation of Thyroid ornithine decarboxylase (ODC) by thyrotropin. I. The rat. Endocrinology 1975; 96: 1403-1412
43. Zusman DR, Burrow GN. Thyroid- stimulating hormone regulation of ornithine decarboxylase activity in the thyroid. Endocrinology 1975; 97: 1089-1095
44. Juvenal GJ, Pisarev MA, Kleiman de Pisarev DL, Altschuler N. Uptake, metabolism and action of triiodothyronine in calf thyroid slices. Mol Cell Endocrinol 1981; 22: 31-40
45. Erkenbrack DE, Rosenberg LL. Binding of thyroid hormones to nuclear extracts of thyroid cells. Endocrinology 1986; 119: 311-317
46. Pisarev MA, Juvenal GJ, Kleiman de Pisarev DL, Chazenbalk GD, Krawiec L, Valsechi RM. Subcellular localization and binding of 125-1 triiodothyronine in calf thyroid. Horm Metab Res 1986; 18: 318-322
47. Juge-Aubry CE, Morin O, Pernin AT, Liang H, Philippe J, Burger AG. Long-lasting effects of TRIAC and thyroxine on the control of thyrotropin and hepatic deiodinase type I. Eur J Endocrinol 1995; 132: 751-758
48. Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 1992; 75: 901-905
49. Schwartz HL, Lazar MA, Oppenheimer JH. Widespread distribution of immunoreactive thyroid hormone β2 in the nuclei of extrapituitary rat tissues. J Biol Chem 1994; 269: 24777-24782
50. Messier N, Langlois MF. Triac regulation of transcription is T(3) receptor isoform- and response element-specific. Mol Cell Endocrinol 2000; 165: 57-66
51. Petty K. Tissue-and cell-specific distribution of proteins that interact with the human thyroid hormone receptor β. Mol Cell Endocrinol 1995; 108: 131-142
52. Allain TJ, Chambers TJ, Flanagan AM, McGregor AM. Tri-iodothyronine stimulates rat osteoclastic bone resorption by an indirect effect. J Endocrinol 1992; 133: 327-331
53. Tarjan G, Stern PH. Triiodothyronine potentiates the stimulatory effects of interleukin-1b on bone resorption and medium interleukin-6 content in fetal rat limb bone cultures. J Bone Miner Res 1995; 10: 1321-1326